Oral Oncology Reports最新文献

{"title":"Comment on prognostic significance of systemic inflammatory markers in oropharyngeal squamous cell carcinoma","authors":"Parth Aphale, Shashank Dokania, Himanshu Shekhar","doi":"10.1016/j.oor.2025.100756","DOIUrl":"10.1016/j.oor.2025.100756","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"15 ","pages":"Article 100756"},"PeriodicalIF":0.0,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144595453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of systemic inflammatory markers in oropharyngeal squamous cell carcinoma","authors":"Jan Horackiewicz ,&nbsp;Matthew Donachie ,&nbsp;Nichola Philp ,&nbsp;Marta Chmielecka ,&nbsp;Mohd Afiq Mohd Slim ,&nbsp;Rhona Hurley ,&nbsp;Catriona M. Douglas","doi":"10.1016/j.oor.2025.100755","DOIUrl":"10.1016/j.oor.2025.100755","url":null,"abstract":"<div><h3>Introduction</h3><div>Incidence of oropharyngeal squamous cell carcinoma (OPSCC) is rising and is increasingly associated with human papillomavirus (HPV) infection, which makes up approximately 50 % of OPSCC cases in the UK. Patients presenting with HPV-positive OPSCC have better overall survival (OS) and prognosis. A significant proportion of these still have poor survival outcomes and identification of these patients remains a challenge. This study aims to investigate the predictive value of albumin, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune inflammation index (SIII) for overall survival in OPSCC.</div></div><div><h3>Methods</h3><div>Seven hundred and twenty-eight patients were extracted from the West of Scotland Cancer Network database and met inclusion criteria with available blood markers at diagnosis. ROC curve analysis was constructed with respect to age, albumin and systemic inflammatory markers to determine diagnostic cut-offs, which were used to stratify subsequent Kaplan-Meier analyses. Univariate and multivariate analysis was carried out with respect to all baseline characteristics.</div></div><div><h3>Results</h3><div>Patients with lowered albumin, LMR and raised NLR, PLR and SIII presented with poorer OS over time as well as median survival times. HPV-negative patients presented with significantly poorer survival outcomes as compared to HPV-positive. Only albumin ≥35.5 g/L (HR = 0.683, 95 %CI 0.538–0.868) and NLR≥4.0 (HR = 1.416, 95 %CI 1.031–1.946) were found to be independent prognostic factors in patients with OPSCC.</div></div><div><h3>Conclusion</h3><div>Serum albumin and NLR represent valuable predictors of survival in OPSCC regardless of HPV status. A universal, diagnostic NLR cut-off remains unknown. Systemic inflammatory markers may be a helpful adjunct when assessing patients during MDT.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"15 ","pages":"Article 100755"},"PeriodicalIF":0.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144471111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Precision-directed therapy in salivary duct carcinoma","authors":"Shambhavi Singh ,&nbsp;Irene George ,&nbsp;Darshana Patil ,&nbsp;Prashant Kumar ,&nbsp;Rajan Datar ,&nbsp;Vijay Haribhakti ,&nbsp;Aditya Shreenivas ,&nbsp;Sewanti Limaye","doi":"10.1016/j.oor.2025.100748","DOIUrl":"10.1016/j.oor.2025.100748","url":null,"abstract":"<div><div>Salivary ductal carcinoma is a rare, aggressive salivary gland carcinoma with poor prognosis and high relapse rate. In recurrent metastatic cases, the median survival is only 5 months. Despite the treatment with multimodal therapeutic strategies, conventional treatments demonstrate a limited effect on long-term survival of the patients. In this study we report two cases of salivary ductal carcinoma patients managed with precision-directed, biomarker-guided therapeutic approaches. In the first case androgen receptor (AR) and HER2 positivity by immunohistochemistry analysis were detected. The patient was treated with AR directed targeted therapy enzalutamide and Leuprolide as maintenance therapy. Disease progression with an emergent HER2 expression by immunohistochemistry led to the inclusion of trastuzumab and pertuzumab. While in the second case the patient progressed on neoadjuvant chemotherapy and the subsequent molecular analysis revealed high expression of PD-L1 and was treated with pembrolizumab in combination with chemotherapy. Follow up assessment revealed treatment durable responses and disease control in both the patients. These cases underscore the potential role of comprehensive molecular profiling-guided personalised therapeutic approaches in the management of advanced SDC patients.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100748"},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of recurrent oral carcinoma cuniculatum with immune checkpoint blockade: A case report and literature review","authors":"William Jones ,&nbsp;Azeem S. Kaka ,&nbsp;Soumon Rudra ,&nbsp;Daniel Lubin ,&nbsp;Faisal Saeed ,&nbsp;Kelly R. Magliocca ,&nbsp;Nabil F. Saba ,&nbsp;Nicole C. Schmitt","doi":"10.1016/j.oor.2025.100746","DOIUrl":"10.1016/j.oor.2025.100746","url":null,"abstract":"<div><h3>Background</h3><div>Carcinoma cuniculatum (CC) is a rare variant of carcinoma that can arise in the oral cavity. CC can be locally aggressive but rarely metastasizes, and there are few reports of treatment with systemic therapy.</div></div><div><h3>Methods</h3><div>We present a case of a 44-year-old man with T4bN0 oral carcinoma cuniculatum of the retromolar trigone.</div></div><div><h3>Results</h3><div>Despite resection with wide margins and adjuvant radiation, the disease recurred 14 months later and was extensive. Following positive margins on a repeat resection, the patient opted for systemic therapy. Despite a PD-L1 combined positive score of 15, the patient did not respond to immunotherapy (pembrolizumab).</div></div><div><h3>Conclusion</h3><div>Though it has a low propensity for metastasis, oral CC is a locally aggressive variant of squamous cell carcinoma, and recurrences are difficult to treat. Although reports of systemic therapy for CC are limited, this case suggests that immunotherapy may have limited activity in this oral cancer variant.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100746"},"PeriodicalIF":0.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144089685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Association between dental exams and diagnosis of head and neck cancer”","authors":"Palanivel Velmurugan,&nbsp;Vinayagam Mohanavel,&nbsp;Kanagasabapathy Sivasubramanian","doi":"10.1016/j.oor.2025.100747","DOIUrl":"10.1016/j.oor.2025.100747","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100747"},"PeriodicalIF":0.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144135090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-driven biomarker discovery for early diagnosis and prognosis in oral oncology","authors":"Suresh Munnangi,&nbsp;Satheeskumar R","doi":"10.1016/j.oor.2025.100749","DOIUrl":"10.1016/j.oor.2025.100749","url":null,"abstract":"<div><div>This study presents an AI-powered multi-omics framework for early detection and prognosis of oral squamous cell carcinoma (OSCC), integrating genomic, transcriptomic, and proteomic data through advanced deep learning architectures. Analysing 1527 OSCC samples from TCGA and GEO databases, we developed a novel multimodal pipeline combining: (1) graph neural networks for heterogeneous data fusion, (2) LASSO regression for robust feature selection, and (3) explainable AI (SHAP, attention mechanisms) for clinical transparency. Our CNN-based diagnostic model demonstrated exceptional performance (accuracy: 93.2 %, 95 % CI: 91.4–94.7; sensitivity: 91.5 % for Stage I tumours; AUC: 0.96), significantly surpassing conventional histopathology (p &lt; 0.001). Three clinically validated biomarker panels were established: (i) a diagnostic panel (TP53/CDKN2A/EGFR, 94.1 % specificity), (ii) an HPV-associated prognostic panel (P16/RB1/E2F1), and (iii) a metastasis prediction panel (TWIST1/VIM/CDH1, C-index = 0.82). Prospective validation in 412 patients showed 43 % reduction in false negatives (15.2 %–8.7 %) with 82 % pathologist concordance. The modular platform addresses critical clinical needs: high-risk screening, therapeutic decision support, and intraoperative margin assessment. IRB-approved implementation confirms real-world viability, positioning this framework as a transformative tool for OSCC precision oncology.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100749"},"PeriodicalIF":0.0,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144070941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Hypofractionated adjuvant radiotherapy in cutaneous squamous cell and basal cell carcinoma of the head and neck: 50 (Gy) in 20 study”","authors":"Efsun Somay ,&nbsp;Erkan Topkan ,&nbsp;Ugur Selek","doi":"10.1016/j.oor.2025.100739","DOIUrl":"10.1016/j.oor.2025.100739","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100739"},"PeriodicalIF":0.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143828722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing efficacy and safety of weekly vs. triweekly cisplatin concurrently with radiotherapy for locally advanced head and neck cancer: Systematic review and meta-analysis","authors":"Mohammed Amine Saâd ,&nbsp;Imad Taleb ,&nbsp;Sofia El Omri ,&nbsp;Hamadoun Traoré ,&nbsp;Imane Chahbounia ,&nbsp;Choukri Elm'hadi ,&nbsp;Saïda Lamine ,&nbsp;Mohammed Anouar Mokhlis ,&nbsp;Lamia Aalaoui ,&nbsp;Mohamed Reda Khmamouche ,&nbsp;Khaoula Alaoui Slimani ,&nbsp;Yassir Sbitti ,&nbsp;Tarik Mahfoud ,&nbsp;Hassan Errihani ,&nbsp;Mohamed Ichou ,&nbsp;Rachid Tanz","doi":"10.1016/j.oor.2025.100738","DOIUrl":"10.1016/j.oor.2025.100738","url":null,"abstract":"<div><h3>Background</h3><div>Cisplatin-based chemotherapy is widely used in the treatment of locally advanced head and neck cancer (HNC). The optimal dosing schedule, whether weekly or triweekly, has been a subject of debate. This study aims to evaluate the efficacy and safety of weekly versus triweekly cisplatin regimens in this patient population.</div></div><div><h3>Material and methods</h3><div>In accordance with the PRISMA guidelines, we conducted this meta-analysis to compare outcomes associated with weekly and triweekly cisplatin regimens. The endpoints examined were overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), locoregional recurrence-free survival (LRRFS) and safety. This meta-analysis protocol was registered in PROSPERO (CRD42023461292).</div></div><div><h3>Results</h3><div>The analysis of survival outcomes demonstrated no difference between the two schedules in terms of OS, PFS, LRRFS and DMFS at 2 and 3 years and 5 years (except for 2 years LRRFS). The odds ratio of OS at 2 years was 1.02 (p = 0.87) at 3 years 0.90 (p = 0.46) and at 5 years 1.13 (p = 0.59), and for PFS at the OR 2 years was 0.97 (p = 0.85) at 3 years 0.87 (p = 0.30) and at 5 years 0.86 (p = 0.55). Triweekly was superior to weekly cisplatin in terms of short-term LRRFS (at 2 years), with an OR of 1.57 (p = 0.02). Both protocols were similar in terms of adverse events.</div></div><div><h3>Conclusion</h3><div>Both weekly and triweekly cisplatin regimens show comparable survival outcomes and safety profiles in patients with head and neck cancers, except for short term LRRFS (at 2 years). These findings suggest that treatment decisions should be tailored to the patient's individual profile, including comorbidities and tolerability. Future studies should explore cumulative dosing and biomarkers to refine treatment strategies further.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100738"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143877461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Change of skeletal muscle mass and associated factors during radiotherapy and chemoradiotherapy in patients with head and neck squamous cell carcinoma","authors":"Anouk W.M.A. Schaeffers ,&nbsp;Hannah A. Scholten ,&nbsp;Annemieke Kok ,&nbsp;Floris C.J. Reinders ,&nbsp;Rebecca K. Stellato ,&nbsp;Ernst J. Smid ,&nbsp;Maartje A. van Beers ,&nbsp;Carla H. van Gils ,&nbsp;Caroline M. Speksnijder ,&nbsp;Marielle P. Philippens ,&nbsp;Lot A. Devriese ,&nbsp;Remco de Bree","doi":"10.1016/j.oor.2025.100737","DOIUrl":"10.1016/j.oor.2025.100737","url":null,"abstract":"<div><h3>Background and purpose</h3><div>The aim is to investigate whether lumbar skeletal muscle index (LSMI) decreases during treatment of head and neck squamous cell carcinoma (HNSCC) patients, and which pre-treatment variables are associated with change.</div></div><div><h3>Materials and methods</h3><div>The LSMI before and during treatment was assessed using MRI scans of HNSCC patients treated with radiotherapy (RT) or chemoradiotherapy (CRT). Mixed models assessed LSMI change and pre-treatment covariates (i.e. age, BMI, tumor characteristics and treatment type).</div></div><div><h3>Results</h3><div>In 63 patients the LSMI decreased from 40.56 cm²/m² to 39.96 cm²/m² (<em>p</em> trend = 0.008) on average. The LSMI of CRT patients decreased more than the LSMI of RT patients, but this was not significant (40.85–39.63 cm²/m² vs. 40.37 to 40.19 cm²/m²; p-interaction = 0.052). No effects of pre-treatment covariates on the LSMI trend over time were observed.</div></div><div><h3>Conclusion</h3><div>LSMI decreased during treatment in HNSCC patients, which was not related to pre-treatment variables, but seemed slightly larger for CRT patients than RT patients.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100737"},"PeriodicalIF":0.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143776663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sinonasal primary squamous cell carcinoma: A case report to illustrate key diagnostic and therapeutic considerations in managing sinonasal squamous cell carcinoma","authors":"A.C. Drossaert ,&nbsp;G.K.P. Bittermann ,&nbsp;P.A.W.H. Kessler","doi":"10.1016/j.oor.2025.100736","DOIUrl":"10.1016/j.oor.2025.100736","url":null,"abstract":"<div><div>Sinonasal squamous cell carcinoma (SNSCC) is a rare malignancy that affects the nasal cavity and paranasal sinuses, representing only 3 % of nasopharyngeal malignancies. It predominantly affects the maxillary sinus, with less frequent involvement of the ethmoid and sphenoid sinuses. SNSCC typically presents with nonspecific symptoms such as epistaxis, pain, and signs of ulceration, often leading to a delayed diagnosis. Due to its late presentation, aggressive nature, and potential for recurrence, SNSCC presents significant challenges in diagnosis and management. A representative clinical case is described to emphasize the importance of a multidisciplinary approach regarding the diagnosis and treatment in managing SNSCC.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"14 ","pages":"Article 100736"},"PeriodicalIF":0.0,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143760969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}